Bristol-Myers Squibb, Johnson and Johnson, Takeda and Onyx have signed on a co-sponsors of the Multiple Myeloma Research Foundation’s (MMRF) Researcher Gateway, a new project that’s being run in conjunction with several hospital and academic cancer research centres. The program is designed to provide open access to patient data, including data on genetic mutations and treatment response, from a 1000-patient multiple myeloma study named Commpass.
The Commpass study has centres around the US and Europe. Bone marrow samples will be taken each time a patient goes into remission and each time they relapse, and all genetic data and treatment response obtained from the patients will be openly shared via the Researcher Gateway portal. “There is going to be new information generated there that you would never get unless you followed patients through first relapse and second relapse and beyond,” said George Mulligan, director of translational medicine for Takeda’s oncology unit.
The program will provide valuable data for the academic centres and pharmaceutical companies, helping them identify new therapeutic targets and select the right patients for new trials.
Read more at Reuters >
The World Orphan Drug Congress Europe brings together pioneers from the orphan drug community, including key opinion leaders from the payer, HTA, public health and patient advocacy bodies. Download the brochure for the World Orphan Drug Congress Europe 2013, 14-15 November 2013, Geneva.